Industry Overview - As of July 17, the medical device industry rose by 0.78%, with a net capital outflow of 178.58 million [1] - A total of 89 stocks in the sector increased, while 31 stocks decreased [1] Top Decliners - The top ten decliners in the sector included: - ST Kelly (-6.72%) - Haooubo (-4.36%) - Tailin Biology (-2.04%) - Mountain Outside Mountain (-1.71%) - Botuo Biology (-1.59%) - Yirui Technology (-1.35%) - DR Sanyou Medical (-1.31%) - Jihigh Development (-1.24%) - Anxu Biology (-1.21%) - Aidi Te (-0.89%) [1][1] Notable Gainers - Notable gainers included: - Anjisi: 7.36% increase with a net capital outflow of 12.83 million - Hualan Co.: 5.22% increase with a net capital outflow of 5.90 million - Xinmai Medical: 5.11% increase with a net capital inflow of 6.21 million - Nanwei Medical: 4.45% increase with a net capital inflow of 19.79 million [1][1][1] Market Sentiment - The overall market sentiment in the medical device sector showed a mixed performance with significant capital outflows from certain stocks while others attracted investment [1]

证券代码：301093 证券简称：华兰股份 公告编号：2025-076 江苏华兰药用新材料股份有限公司 关于公司取得金融机构股票回购专项贷款承诺函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 本次回购股份的基本情况 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025 年 7 月 12 日在巨潮资讯网（www.cninfo.com.cn）上披露的 《关于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份 的回购报告书》（以下简称"《回购报告书》"）。 根据《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集中竞 价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元 （含）且不超过人民币 20,000 万元（含），其中超募 ...

Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. plans to repurchase its shares using raised funds, self-owned funds, and self-raised funds through centralized bidding, with a total repurchase amount between RMB 100 million and RMB 200 million [1][2]. Summary by Sections Share Repurchase Plan - The company will use a total of no less than RMB 100 million and no more than RMB 200 million for the share repurchase, with raised funds accounting for no less than RMB 70 million and no more than RMB 140 million [2]. - The maximum repurchase price is set at RMB 45.50 per share, with the repurchase period not exceeding 12 months from the date of shareholder meeting approval [2]. Adjustments Post-Equity Distribution - Following the implementation of the 2024 annual equity distribution, the maximum repurchase price will be adjusted to RMB 34.84 per share, effective from July 14, 2025 [3]. - The repurchase will include shares for employee stock ownership plans or equity incentives, with specific quantities and funding sources detailed in the report [3][4]. Debt Creditor Information - Creditors have the right to request debt repayment or guarantees within 30 days of notification or 45 days from the announcement date, with the company continuing to fulfill obligations as per original debt agreements [4][5]. - Required materials for debt claims include contracts and identification documents, with specific submission methods outlined [5].

证券代码：301093 证券简称：华兰股份 公告编号：2025-075 江苏华兰药用新材料股份有限公司 关于回购股份减少注册资本通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 通知债权人的原由 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025年 7月 12日在巨潮资讯网（www.cninfo.com.cn）上披露的《关 于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份的回 购报告书》（以下简称"《回购报告书》"）。 根据公司《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集 中竞价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含），其中超募资金不低于人民币 ...

公司于 2025年 6月 23日召开了第六届董事会第二次会议，审议通过了《关 于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份方案 的议案》，该议案已经公司于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会 逐项审议通过。具体内容详见公司于 2025 年 7 月 12 日在巨潮资讯网 （www.cninfo.com.cn）上披露的《关于使用超募资金、自有资金及自筹资金以 集中竞价交易方式回购公司股份的回购报告书》（以下简称"《回购报告书》"）。 证券代码：301093 证券简称：华兰股份 公告编号：2025-074 江苏华兰药用新材料股份有限公司 关于 2024 年年度权益分派实施后调整回购股份价格上限的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 江苏华兰药用新材料股份有限公司（以下简称"公司"）2024年年度权益分 派实施后，公司使用超募资金、自有资金及自筹资金以集中竞价交易方式回购 股份的价格上限由不超过人民币 45.50 元/股（含）调整为不超过人民币 34.84 元 /股（含）。公司本次对回购股 ...

[2025 Semi-Annual Performance Forecast](index=1&type=section&id=Jiangsu%20Hualan%20Pharmaceutical%20New%20Material%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Forecast) [Performance Forecast Overview](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company anticipates a year-on-year increase in its 2025 first-half performance, with net profit attributable to shareholders projected between 38 million CNY and 49.4 million CNY, representing a 2.77% to 33.60% growth, and non-recurring net profit between 30 million CNY and 39 million CNY, up 22.50% to 59.25% Performance Forecast Summary | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | Profit: 38.00 million CNY - 49.40 million CNY | Profit: 36.9762 million CNY | | Year-on-Year Change | Increase: 2.77% — 33.60% | - | | **Net Profit After Deducting Non-Recurring Gains and Losses** | Profit: 30.00 million CNY - 39.00 million CNY | Profit: 24.4894 million CNY | | Year-on-Year Change | Increase: 22.50% — 59.25% | - | | **Basic Earnings Per Share** | Profit: 0.30 CNY/share - 0.39 CNY/share | Profit: 0.29 CNY/share | [Reasons for Performance Change](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Change) During the reporting period, the company's performance growth was primarily driven by enhanced market development and expanded sales channels, leading to a simultaneous increase in sales orders, revenue, and gross profit - The core drivers of the company's performance growth are market development and sales channel expansion, directly leading to an increase in sales orders, sales revenue, and gross profit compared to the prior period[6](index=6&type=chunk) [Risk Warning and Disclaimer](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The company's preliminary, unaudited performance forecast has been pre-communicated with auditors without disagreement, with final figures subject to the official 2025 semi-annual report, urging investor caution - This performance forecast data represents preliminary estimates by the company's finance department and remains unaudited[4](index=4&type=chunk)[7](index=7&type=chunk) - The company has pre-communicated with the annual report auditing accounting firm regarding this performance forecast, with no disagreements identified[4](index=4&type=chunk) - The company advises investors that specific financial data will be subject to the officially disclosed 2025 semi-annual report, urging cautious decision-making and awareness of investment risks[7](index=7&type=chunk)

Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. plans to repurchase its shares using raised funds, self-owned funds, and self-raised funds, with a total repurchase amount between RMB 100 million and RMB 200 million, aimed at capital reduction and employee stock ownership plans [1][2][16]. Summary by Sections Repurchase Funding Sources - The total repurchase amount will not be less than RMB 100 million and not exceed RMB 200 million, with raised funds between RMB 30 million and RMB 60 million, and self-owned and self-raised funds between RMB 70 million and RMB 140 million [1][16]. Purpose of Repurchase - The repurchased shares will be used for capital reduction and employee stock ownership plans or equity incentives. Shares bought with raised funds will be canceled, while those bought with self-owned and self-raised funds may be used for employee incentives in the future [1][13][16]. Types and Methods of Shares to be Repurchased - The shares to be repurchased are ordinary shares (A shares) and will be acquired through centralized bidding [2][12]. Repurchase Timeline and Price - The repurchase period will not exceed 12 months from the date of the shareholders' meeting approval, with a maximum price of RMB 45.50 per share [2][15]. Shareholder Reduction Plans - Major shareholder Ruizhong Life Insurance Co., Ltd. plans to reduce its holdings by up to 3,789,267 shares (3.00% of total shares) between June 4, 2025, and September 3, 2025 [2][20]. Financial Impact and Company Structure - As of March 31, 2025, the total assets of the company were approximately RMB 2.51 billion, and the repurchase funds will account for about 7.98% of total assets and 8.83% of equity attributable to shareholders [17][22]. Compliance and Approval - The repurchase plan has been approved by the board and will comply with relevant laws and regulations, ensuring it does not harm the interests of the company or its shareholders [26][27].

证券代码：301093 证券简称：华兰股份 公告编号：2025-072 江苏华兰药用新材料股份有限公司 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 回购公司股份的回购报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 回购资金来源：超募资金、自有资金及自筹资金。 回购资金总额：本次用于回购的资金总额不低于人民币 10,000 万元（含） 且不超过人民币 20,000 万元（含），其中超募资金不低于人民币 3,000 万元（含） 且不超过人民币 6,000 万元（含），自有资金及自筹资金不低于人民币 7,000 万 元（含）且不超过人民币 14,000万元（含）。具体回购资金总额以回购期满时实 际回购股份使用的资金总额为准。 回购用途：江苏华兰药用新材料股份有限公司（以下简称"公司"）本次 回购的股份将用于注销并减少公司注册资本以及员工持股计划或者股权激励， 其中使用超募资金回购的股份将依法予以注销并减少公司注册资本，使用自有 资金及自筹资金回购的股份在未来适宜时机用于员工持股计划或者股权激励。 回购股份的种类：公司发行的人民币普 ...

特别提示： 1、 本次股东会未出现否决议案的情形。 一、 会议召开和出席情况 （一） 会议召开时间 通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 7 月 11 日 （星期五）9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 7 月 11 日 （星期五）9:15-15:00。 证券代码：301093 证券简称：华兰股份 公告编号：2025-071 江苏华兰药用新材料股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 （二） 现场会议召开地点：江苏省江阴市申港镇镇澄路 1488 号江苏华兰 药用新材料股份有限公司会议室。 2、 本次股东会未涉及变更以往股东会已通过的决议。 3、 本次股东会审议各项议案均对中小股东的表决单独计票。 1、 现场会议召开时间：2025 年 7 月 11 日（星期五）下午 14:30 2、 网络投票时间：2025 年 7 月 11 日（星期五） （三） 会议召开方式：采取现场投票与网络投票相 ...

北京植德律师事务所 关于江苏华兰药用新材料股份有限公司 2025 年第三次临时股东会的 法律意见书 植德京(会)字[2025]0099 号 二〇二五年七月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 www.meritsandtree.com 北京植德律师事务所 2025年第三次临时股东会的 法律意见书 植德京(会)字[2025]0099号 致：江苏华兰药用新材料股份有限公司 北京植德律师事务所（以下简称"本所"）接受江苏华兰药用新材料股份有 限公司（以下简称"公司"或"华兰股份"）的委托，指派律师出席并见证公司 2025年第三次临时股东会（以下简称"本次会议"）。 关于江苏华兰药用新材料股份有限公司 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》 ...